92 results about "Glucose homeostasis" patented technology

Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used, in combination with agonists of glucagon-like peptide-1 (GLP-1), to treat non-insulin dependent diabetes mellitus, optionally with other therapies, by improving glycemic control while minimizing side effects, such as heart hypertrophy and elevated fed-state plasma glucose, which are associate with both TZD and GLP-1 monotherapies. Thus, the co-administration of TZD and GLP-1 helps regulate glucose homeostasis in Type II diabetic patients.

Methods of treating diabetes mellitus in a patient in need of such treatment include administering an effective amount of an insulin drug to the patient in order to treat diabetes mellitus in the patient. Methods according to the present invention may “activate” the liver, potentially restoring normal glucose homeostasis to individuals suffering from diabetes mellitus.

The present invention provides methods, systems and apparatuses for effecting excitation or inhibition of small sensory nerve fibers, such as C-afferent fibers, by electrical stimulation of nerves innervating the pancreas in diabetic subjects. In an aspect the methods are directed to effecting insulin production and for the treatment of diabetes. This invention includes a closed or open loop feedback control system in which biomarker levels are monitored in order to direct electrical stimulation. An implantable or external neural stimulation device is also provided.

The invention discloses compound functional sugar with a function of reducing food glycemic indexes, which contains L-arabinose, functional oligosaccharide, dietary fiber and a mulberry leaf extract. The compound functional sugar has the benefits that the metabolism of cane sugar and starch in a human body is influenced; the blood glucose response of the cane sugar and the starch can be reduced, so that the area under a glucose curve becomes gentle, and the GI values of the cane sugar and the starch are reduced; meanwhile, the secretion of insulin can be reduced, so that the area under an insulin curve becomes gentle; and the insulin and the cumulative area ratio under a blood glucose response curve are represented to be reduced, and the compound functional sugar is prompted, so that the human body secretes a small quantity of insulin to maintain glucose homeostasis.

The present invention relates to methods and compounds for regulating glucose metabolism, achieving glucose homeostasis, and decreasing blood glucose levels. Methods and compounds for treating or preventing diabetes, hyperglycemia, and disorders and conditions associated with altered or impaired glucose metabolism are also provided.

Aryl 119 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

This invention relates to a pet food composition for regulating body weight and preventing obesity and related disorders in pets, which comprises as an active ingredient at least one plant or plant extract having the ability to stimulate energy expenditure and / or fat burning. The invention also relates to a method for improving the health of pets, particularly by preventing obesity and metabolic disorders associated with obesity in pets. It also relates to a method for increasing energy expenditure, controlling the glucose homeostasis and improving activity or mobility of the pet.

This invention is of particular use to patients with Diabetes Mellitus. It uses alkyl analogs of the methyl pyruvate (MP) family to provide energy and improve insulin and glucose homeostasis via accelerated intracellular delivery of protons and ATP from each MP. The energy upregulates cellular cross talk and networking resulting in a surge of ATP enabling NADH (via glycolysis) that enables pancreatic islet cells to obtain increased ATP allowing excess insulin manufacture. This process improves cellular respiration and expedites protein, lipid and hormone manufacture. The increased energy also enables telomeres and delays Hayflick limit. Instead of cellular repair, silence, or apoptosis, energy is allocated for cell / organ function. This invention curbs inflammation and ROS by idealizing cellular respiration and diminishing hyperglycemia. In turn a reduction of advanced glycation end products (AGEs), lessened target RNA and nucleic acid toxins, i.e., diminished HbA1c occurs. By decreased drain of cellular energy, genomic function improves.

The present invention encompasses the use of compounds for a novel approach to treat and prevent diseases, conditions, and disorders such as diabetes and ischemic reperfusion injury. Compounds of the invention, including but not limited to BAM15((2-fluorophenyl){6-[(2-fluorophenyl)amino](1,2,5-oxadiazolo[3,4-e]pyrazin-5-yl)}amine), a mitochondrial uncoupler, can improve glucose tolerance, increases cellular oxygen consumption, treat or prevent kidney ischemia reperfusion injury reverse insulin resistance, reverse or treat hyperinsulinemia, and reverse or treat hyperlipidemia. The present invention further provides novel compounds as well as methods for identifying compounds with the same or similar properties as BAM15.

The present invention provides methods, systems and apparatuses for effecting excitation or inhibition of small sensory nerve fibers, such as C-afferent fibers, by electrical stimulation of nerves innervating the pancreas in diabetic subjects. In an aspect the methods are directed to effecting insulin production and for the treatment of diabetes. This invention includes a closed or open loop feedback control system in which biomarker levels are monitored in order to direct electrical stimulation. An implantable or external neural stimulation device is also provided.

α2-Heremans Schmid Glycoprotein (AHSG) inhibits insulin-induced autophosphorylation of the insulin receptor (IR) and IR-tyroskine kinase (TK) activity; genetic ablation of the Ahsg gene enhances insulin signal transduction and increase whole-body insulin sensitivity. Therefor, AHSG and its gene(s) are useful targets for agents that inhibit the development or progression of Type II diabetes or any disease or disorder associated with increased insulin resistance. Provided herein is a method for inhibiting the biological activity of AHSG protein in a cell using compounds that inhibit phosphorylation of AHSG. Also disclosed is a method of augmenting the phosphorylation or IR-TK activity in a liver or muscle cell by providing a compound that lowers the amount of active AHSG or inhibits the biological activity of AHSG. Such effects may be achieved by delivering an antisense nucleic acid construct that hybridizes with AHSG encoding DNA. This invention includes a method (a) treating a subject that is susceptible to, or suffers from, obesity and insulin resistance or (b) increasing insulin sensitivity, and thereby preventing or treating insulin resistance in the subject. The method comprises lowering the amount of active AHSG or inhibiting the biological activity of AHSG in the subject, preferably in liver or muscle, by using AHSG antisense constructs or an anti-AHSG antibody. In a subject eating a high fat diet, the effect on body weight gain and / or insulin resistance is diminished, and total body fat content is lowered, by lowering the amount of active AHSG or inhibiting the action of the AHSG in the subject using the agents noted above.

The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitisers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.

The present invention relates to a Akkermansia muciniphila SNUG-61027 strain (accession number KCTC 13530BP) and a use thereof. Specifically provided are: a composition for appetite control or prevention, improvement, alleviation or treatment of metabolic diseases, containing, as an active ingredient, the strain, a culture liquid thereof and the like, or a B2UM07 protein isolated therefrom; a use of the composition for appetite control or prevention, improvement, alleviation and treatment of metabolic diseases; and a method for appetite control or prevention, improvement, alleviation and treatment of metabolic diseases by using the composition. Therefore, the present invention exhibits effects of weight loss and glucose homeostasis control, from among anti-obesity effects, and influence on brown fat and secretion of an appetite control hormone secretion.

Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a drop in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and / or nitrate.

The invention provides methods, compositions, uses of compositions, assays and kits for modulating brown adipose tissue (BAT) in animals and patients with obesity, insulin resistance and perturbed glucose homeostasis are disclosed. Accordingly, methods, compositions, uses of compositions, and kits are useful for the amelioration of pathological conditions characterized by storage of excess energy, insulin resistance and related metabolic syndromes often associated with obesity.

The invention provides a Chinese medicinal preparation for treating diabetes, which is prepared from heterophylly falsestarwort root, gypsum, Indian buead, pollen, dwarf lilyturf tuber, cochinchnese asparagus root, chicken gizzard-membrane, tortoise plastron, dendrobium, turtle shell, medlar, cinnamomvine, common macrocarpium fruit, villous amomum fruit, root of rehmannia, Chinese magnoliavine fruit, dark plum fruit, pangolin, root of straight ladybell, fragrant solomonseal rhizome, common anemarrhena rhizome, dragon's bones and oyster shell according to a conventional Chinese medicament preparation process. The preparation is a pure Chinese medicinal preparation, is used for the treatment of the diabetes and complicating diseases thereof, and has the advantages of having steady therapeutic effect, having no toxic side effect, adjusting the environment in organisms, improving the constitution, relieving the state of insulin resistance, adjusting glycolipid metabolism, strengthening glucose homeostasis and the like.

N-fatty acid-amino acid conjugates and J2 prostanoid-amino acid conjugates are disclosed along with methods for making such conjugates and methods of using these conjugates in the treatment of conditions that involved dysfunctional lipid metabolism, insulin sensitivity, glucose homeostasis, and / or inflammation.

The present invention encompasses the use of compounds for a novel approach to treat and prevent diseases, conditions, and disorders such as diabetes and ischemic reperfusion injury. Compounds of the invention, including but not limited to BAM15 ((2-fluorophenyl){6-[(2-fluorophenyl)amino](1,2,5-oxadiazolo[3,4-e]pyrazin-5-yl)}amine), a mitochondrial uncoupler, can improve glucose tolerance, increases cellular oxygen consumption, treat or prevent kidney ischemia reperfusion injury reverse insulin resistance, reverse or treat hyperinsulinemia, and reverse or treat hyperlipidemia. The present invention further provides novel compounds as well as methods for identifying compounds with the same or similar properties as BAM15.

The invention discloses konjac cereal recombined rice beneficial for glucose homeostasis and a preparation method thereof. The konjac cereal recombined rice is prepared from the raw materials in partsby weight: 0-30 parts of konjac glucomannan, 2-5 parts of soybeans, 5-15 parts of oats, 10-30 parts of sorghum, 3-12 parts of red kidney beans, 7-15 parts of black rice, 1-5 parts of proso millet, 15-35 parts of wheat, 1-4 parts of hyacinth beans and 0.3-1.2 parts of monostearin. The konjac cereal recombined rice is reasonable in energy proportion, and energy supply of protein, fat and carbohydrate of the rice is close to the level of natural cereals; the cooking performance is good, the taste is close to that of natural rice, and the common problems of cooking intolerance and soft taste of similar products sold in the market are solved; animal experiments show that multiple glucolipid metabolism indexes can be effectively regulated after long-time eating, glucose homeostasis of bodies isfacilitated, and the konjac recombined rice is the first rice for assisting blood sugar level decreasing function evaluation through animal models. Meanwhile, the product is special in color and hasrich cereal fragrance, the flavor and taste accord with the eating habit of the masses for traditional staple food, and consumers can conveniently eat the rice for a long time.

A method to identify a candidate compound for use in the treatment of a condition involving dysregulation of glucose homeostasis or of glucose uptake in a mammal, by identifying a candidate compound that causes an increase in translocation of GLUT without causing an increase in the production of cAMP. A kit for use in such a method. A method of treatment of a condition involving dysregulation of glucose homeostasis or of glucose uptake in a mammal and a compound for use in such a method.

Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and / or nitrate.

Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and / or nitrate.

Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and / or nitrate.

Methods and compositions for enhancing fertility and / or inhibiting pregnancy failure, restoring glucose tolerance and / or preventing glucose intolerance and / or maintaining glucose homeostasis and / or inducing or enhancing weight loss, treating dyslipidemia, treating hypertestosteronism or hyperandrogenism, and / or treating type 2 diabetes in an individual in need thereof are provided. These involve compositions that inhibit expression of interferon-gamma (IFN-gamma) or a downstreamIFN-gamma-stimulated gene, which is preferably a macrolide immunosuppressant compound.

Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and / or nitrate.

The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitizers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.

Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and / or nitrate.

The present invention provides reagents and methods for identifying inhibitors of the L-type Ca2+ channel β3 protein, which has been demonstrated to be involved in calcium signaling, insulin secretion, and glucose homeostasis. The invention also provides therapeutics and methods for treating a subject with one or more of diabetes, insulin resistance, impaired insulin secretion, and impaired glucose homeostasis, involving the use of inhibitors of an L-type Ca2+ channel β3 subunit to provide a benefit to the subject.

Weight loss agents include compounds defined by Formula I or a pharmaceutically acceptable salt or prodrug thereof, compositions containing the same, and methods of use thereof are described herein. In some embodiments, the compound is Withaferin A. In other embodiments, the compound is Michael addition product of Withaferin A. The compounds can be administered to induce weight loss in a pre-obese, obese, or morbidly obese patient, reduce body fat in a pre-obese, obese, or morbidly obese patient, reduce food intake in a pre-obese, obese, or morbidly obese patient, improve glucose homeostasis in a pre-obese, obese, or morbidly obese patient, or combinations thereof.

Described herein are methods and materials for improving whole body glucose homeostasis in a subject. The methods and materials described herein are useful for preventing, delaying, and / or treating insulin-related diseases and conditions, including but not limited to type I and II diabetes, chronic pancreatitis, pancreatectomy, insulin resistance, prediabetes, and age-related insulin resistance, by increasing the efficiency of insulin secretion by β cells, and increasing the sensitivity of peripheral tissues, including skeletal muscle and adipose tissues.